BRIEF published on 02/12/2025 at 11:35, 1 year 5 months ago Sensorion to Participate in ARO 48th Annual Midwinter Meeting Sensorion Hearing Loss ARO Meeting GJB2-GT Therapy Biotech Conference
BRIEF published on 02/12/2025 at 11:35, 1 year 5 months ago Sensorion participera à la 48e réunion annuelle de mi-hiver de l'ARO Sensorion Perte Auditive Réunion De L'ARO Thérapie GJB2-GT Conférence Sur Les Biotechnologies
PRESS RELEASE published on 02/12/2025 at 11:30, 1 year 5 months ago Inside Information / Other news releases Sensorion announces participation in ARO 48th Annual Midwinter Meeting with focus on gene therapy for deafness. Details of presentations by Sensorion executives included Gene Therapy Sensorion ARO Meeting Deafness Sensorion Executives
PRESS RELEASE published on 02/12/2025 at 11:30, 1 year 5 months ago Informations privilégiées / Autres communiqués Sensorion participe à la 48ème rencontre annuelle de l'ARO pour présenter ses thérapies novatrices contre la perte auditive Sensorion Perte Auditive Thérapies ARO Rencontre Annuelle
BRIEF published on 12/27/2024 at 07:35, 1 year 7 months ago Sensorion Completes Enrollment for Audiogene Phase 1/2 Trial Gene Therapy Sensorion Hearing Loss SENS-501 Audiogene Trial
BRIEF published on 12/27/2024 at 07:35, 1 year 7 months ago Sensorion finalise le recrutement pour l'essai de phase 1/2 d'Audiogene Thérapie Génique Sensorion Perte Auditive SENS-501 Essai Audiogene
PRESS RELEASE published on 12/27/2024 at 07:30, 1 year 7 months ago Inside Information / Other news releases Sensorion completes enrollment of the first cohort in the Audiogene Phase 1/2 gene therapy clinical trial, targeting infants with hearing loss disorders Gene Therapy Clinical Trial Sensorion Hearing Loss Disorders Audiogene
BRIEF published on 12/18/2024 at 07:35, 1 year 7 months ago Sensorion présente des résultats préliminaires positifs pour le SENS-501 Essai Clinique Thérapie Génique Innovation Biotechnologique SENS-501 Surdité Congénitale
BRIEF published on 12/18/2024 at 07:35, 1 year 7 months ago Sensorion Reports Positive Preliminary Results for SENS-501 Gene Therapy Clinical Trial SENS-501 Congenital Deafness Biotechnological Innovation
PRESS RELEASE published on 12/18/2024 at 07:30, 1 year 7 months ago Informations privilégiées / Autres communiqués Sensorion présente des données positives de l'essai clinique de Phase 1/2 de thérapie génique pour la surdité chez les nourrissons. Nouvelles données encourageantes sur SENS-501. Séminaire en ligne prévu pour 2025 Sécurité Thérapie Génique Phase 1/2 Sensorion Surdité
Published on 08/01/2026 at 01:58, 2 days 16 hours ago Clôture de l'option sur la propriété de graphite au Québec
Published on 08/01/2026 at 01:20, 2 days 17 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 17 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 17 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/03/2026 at 17:59, 20 minutes ago Original-Research: Reply SpA (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 08/03/2026 at 16:45, 1 hour 34 minutes ago Fuller, Smith & Turner PLC: Total Voting Rights, Issue of Shares and Treasury Shares
Published on 08/03/2026 at 16:45, 1 hour 34 minutes ago Thailand - Canada Pilot Carbon Capture in Cement Industry to Advance Net Zero 2050
Published on 08/03/2026 at 17:45, 35 minutes ago Monthly disclosure of the total number of shares and voting rights - July 2026
Published on 08/03/2026 at 17:45, 35 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
